With a one year PEG ratio of 1,171.36, Elanco Animal Health Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.41% of US stocks.
ELAN's went public 1.53 years ago, making it older than just 1.79% of listed US stocks we're tracking.
ELAN's current price/earnings ratio is 109.23, which is higher than 96.43% of US stocks with positive earnings.
If you're looking for stocks that are quantitatively similar to Elanco Animal Health Inc, a group of peers worth examining would be HOLX, HSTM, OTEX, AGCO, and PRGO.
ELAN's SEC filings can be seen here. And to visit Elanco Animal Health Inc's official web site, go to www.elanco.com.
Elanco Animal Health Incorporated (ELAN) Company Bio
Elanco Animal Health Incorporated operates as an animal health care company. The Company develops, manufactures, and markets products for companion and food animals. Elanco Animal Health serves clients worldwide. The company is based in Greenfield, Indiana.
ELAN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Elanco Animal Health Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Elanco Animal Health Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Elanco Animal Health Inc ended up being:
The company's compound free cash flow growth rate over the past 1.48 years comes in at -0.62%; that's greater than only 1.3% of US stocks we're applying DCF forecasting to.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 60.28% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ALC, AMPH, CSII, HAPP, and MEDS can be thought of as valuation peers to ELAN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.